New therapeutics for cancer and inflammatory diseases targeting fibroblast immunology

Urgently advancing first-in-class antibodies to clinic

Activated fibroblasts play an important and often overlooked role in driving the immune system’s response in cancer and inflammatory diseases. At Mestag, we are developing critically needed new therapies that harness fibroblast immunology to re-establish the immune system’s proper function for patients who do not benefit from current treatments. 

Our portfolio includes M300, a bispecific antibody designed to generate a robust and specialized immune response against cancer cells via the formation of tertiary lymphoid structures (TLSs) in solid tumors. M300 is rapidly progressing towards its first clinical trial. We are also pioneering agonist antibodies targeting a stromal inhibitory receptor through our M402 program to dampen down an over-active immune system and address critical unmet needs in inflammatory disease, such as RA, IBD and lupus. 

Our vision is significantly improved lives for people affected by inflammatory disease and cancer.